{"id":109,"date":"2019-09-22T17:51:56","date_gmt":"2019-09-22T17:51:56","guid":{"rendered":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/chapter\/3-8-monobactams\/"},"modified":"2021-12-07T11:06:20","modified_gmt":"2021-12-07T11:06:20","slug":"3-8-monobactams","status":"publish","type":"chapter","link":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/chapter\/3-8-monobactams\/","title":{"raw":"3.8 Monobactams","rendered":"3.8 Monobactams"},"content":{"raw":"Like penicillins, cephalosporins, and carbapenems, monobactams also have a beta-lactam ring structure.\n\nIndications:<\/strong> Monobactams are narrow-spectrum antibacterial medications that are used primarily to treat gram-negative bacteria such as Pseudomonas aeruginosa.\n\nMechanism of Action:<\/strong> Monobactams are bactericidal and work to inhibit bacterial cell wall synthesis.[footnote]This work is a derivative of Microbiology<\/a> by OpenStax<\/a> licensed under CC BY 4.0<\/a>. Access for free at https:\/\/openstax.org\/books\/microbiology\/pages\/1-introduction<\/a>[\/footnote]\n\nSpecific Administration Considerations:<\/strong> Patients taking monobactams may experience adverse effects similar to other beta-lactam medications, so nurses should monitor for GI symptoms, skin sensitivities, and coagulation abnormalities.\n\nPatient Teaching & Education: <\/strong>Patients should monitor for signs of superinfection and report any occurrence to the provider. If the patient experiences fever and bloody diarrhea, they should contact the provider immediately.\u00a0 The patient should also be advised to notify the provider immediately if symptoms progress or if any sign of allergic response occurs.[footnote]uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]<\/sup>\n\nNow let's take a closer look at the medication grid for aztreonam in Table 3.8.[footnote]Daily Med, https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm<\/a>, used for hyperlinked medications in this module. Retrieved June 27, 2019.[\/footnote]\n\nTable 3.8 Monobactam Medication Grid\n\n\n\n\n
Class\/Subclass<\/strong><\/th>\nPrototype\/Generic<\/strong><\/th>\nAdministration Considerations<\/strong><\/th>\nTherapeutic Effects<\/strong><\/th>\nSide\/Adverse Effects<\/strong><\/th>\n<\/tr>\n
Monobactams<\/th>\naztreonam<\/a><\/td>\nCheck for allergies to any beta lactams - penicillin, cephalosporins, or carbapenems\n\nCan be administered IM, IV, or via inhalation<\/td>\nMonitor for systemic signs of infection:\n\n-WBCs\n\n-Fever\n\nMonitor actual site of infection\n\nMonitor culture results, if obtained<\/td>\nSimilar to cephalosporins<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \n

Critical Thinking Activity 3.8a <\/strong><\/h2>\nUsing the above grid information, consider the following clinical scenario question:<\/strong>\n\nA patient with cystic fibrosis is diagnosed with ventilator-associated pneumonia and is prescribed Aztreonam 1 gm IV daily for a suspected Pseudomonas aeruginosa infection. The nurse reviews the culture results that just arrived and notices that the results indicate the infection is caused by Methicillin-resistant Staphylococcus aureus. Will this medication be effective against this bacteria? What is the nurse's next best response?\n\nNote: Answers to the Critical Thinking activities can be found in the \"Answer Key\" sections at the end of the book.","rendered":"

Like penicillins, cephalosporins, and carbapenems, monobactams also have a beta-lactam ring structure.<\/p>\n

Indications:<\/strong> Monobactams are narrow-spectrum antibacterial medications that are used primarily to treat gram-negative bacteria such as Pseudomonas aeruginosa.<\/p>\n

Mechanism of Action:<\/strong> Monobactams are bactericidal and work to inhibit bacterial cell wall synthesis.[1]<\/sup><\/a><\/p>\n

Specific Administration Considerations:<\/strong> Patients taking monobactams may experience adverse effects similar to other beta-lactam medications, so nurses should monitor for GI symptoms, skin sensitivities, and coagulation abnormalities.<\/p>\n

Patient Teaching & Education: <\/strong>Patients should monitor for signs of superinfection and report any occurrence to the provider. If the patient experiences fever and bloody diarrhea, they should contact the provider immediately.\u00a0 The patient should also be advised to notify the provider immediately if symptoms progress or if any sign of allergic response occurs.[2]<\/sup><\/a><\/sup><\/p>\n

Now let’s take a closer look at the medication grid for aztreonam in Table 3.8.[3]<\/sup><\/a><\/p>\n

Table 3.8 Monobactam Medication Grid<\/p>\n\n\n\n\n
Class\/Subclass<\/strong><\/th>\nPrototype\/Generic<\/strong><\/th>\nAdministration Considerations<\/strong><\/th>\nTherapeutic Effects<\/strong><\/th>\nSide\/Adverse Effects<\/strong><\/th>\n<\/tr>\n
Monobactams<\/th>\naztreonam<\/a><\/td>\nCheck for allergies to any beta lactams – penicillin, cephalosporins, or carbapenems<\/p>\n

Can be administered IM, IV, or via inhalation<\/td>\n

Monitor for systemic signs of infection:<\/p>\n

-WBCs<\/p>\n

-Fever<\/p>\n

Monitor actual site of infection<\/p>\n

Monitor culture results, if obtained<\/td>\n

Similar to cephalosporins<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Critical Thinking Activity 3.8a <\/strong><\/h2>\n

Using the above grid information, consider the following clinical scenario question:<\/strong><\/p>\n

A patient with cystic fibrosis is diagnosed with ventilator-associated pneumonia and is prescribed Aztreonam 1 gm IV daily for a suspected Pseudomonas aeruginosa infection. The nurse reviews the culture results that just arrived and notices that the results indicate the infection is caused by Methicillin-resistant Staphylococcus aureus. Will this medication be effective against this bacteria? What is the nurse’s next best response?<\/p>\n

Note: Answers to the Critical Thinking activities can be found in the “Answer Key” sections at the end of the book.<\/p>\n

  1. This work is a derivative of Microbiology<\/a> by OpenStax<\/a> licensed under CC BY 4.0<\/a>. Access for free at https:\/\/openstax.org\/books\/microbiology\/pages\/1-introduction<\/a> ↵<\/a><\/li>
  2. uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a> ↵<\/a><\/li>
  3. Daily Med, https:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm<\/a>, used for hyperlinked medications in this module. Retrieved June 27, 2019. ↵<\/a><\/li><\/ol><\/div>","protected":false},"author":2,"menu_order":8,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":"cc-by"},"chapter-type":[49],"contributor":[],"license":[53],"class_list":["post-109","chapter","type-chapter","status-publish","hentry","chapter-type-numberless","license-cc-by"],"part":84,"_links":{"self":[{"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":1,"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/109\/revisions"}],"predecessor-version":[{"id":110,"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/109\/revisions\/110"}],"part":[{"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/84"}],"metadata":[{"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/109\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/wp\/v2\/media?parent=109"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=109"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/wp\/v2\/contributor?post=109"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/pressbooks.publishdot.com\/nursingpharmacology\/wp-json\/wp\/v2\/license?post=109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}